

COPIES OF PAPERS
ORIGINALLY FILED

PATENT

RECEIVED

SEP 13 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Ruth Gimeno and
Fong-Ying Tsai

Serial No.: 10/086,181

Filed: February 26, 2002

For: Methods for the Treatment of Metabolic
Disorders, Including Obesity and Diabetes

Attorney Docket No.: MNI-220

Group Art Unit: 1645

Examiner: Not yet assigned

Commissioner for Patents
Washington, D.C. 20231

Certificate of First Class Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

Sept. 4, 2002

Date of Signature and of Mail Deposit

By:

Maria Laccotripe

Maria Laccotripe Zacharakis, Ph.D.

Limited Recognition Under 37 CFR §10.9(b)

Attorney for Applicants

**DECLARATION OF MILLENNIUM PHARMACEUTICALS, INC.
PURSUANT TO 37 C.F.R § 1.48(a)(5)**

Dear Sir:

Millennium Pharmaceuticals, Inc. certifies under 37 C.F.R. § 1.48(a)(5) that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of an assignment from the inventors of the patent application identified above.

U.S. Serial No.: 10/086,181


Millennium Pharmaceuticals, Inc. consents to adding Fong-Ying Tsai as an inventor in the above-identified Patent Application.

The undersigned has reviewed all the documents in the chain of title of U.S. Patent Application Serial No. 10/086,181 and, to the best of the undersigned's knowledge and belief, title lies with Millennium Pharmaceuticals, Inc.

The undersigned (whose title is supplied below) is empowered to sign this certificate on behalf of the assignee, Millennium Pharmaceuticals, Inc.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

7/1/02
Date


Name: Scott A. Brown, Esq.
Title: Vice President and
Chief Patent Counsel